Primary Health Care Limited

At Primary Health Care, our purpose is to help all Australians be healthy and well. Our extensive network of medical centers with General Practice, pathology labs, diagnostic imaging and more offer patients the convenience of seamless medical services, whilst Healthcare Practitioners enjoy working in unique multi-disciplinary environments where they can pursue clinical excellence and innovative care. We are committed to shaping the future of Australian healthcare. From a single medical centre in 1985, our passion for delivering total care has seen us become the choice of over 2 million Australian patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CVS HEAD OF SPECIALTY PHARMACY SEES FUTURE OF HEALTHCARE AT HOME AFTER COVID-19

Medcity news | May 26, 2020

news image

Mail-order prescriptions are nothing new, but pharmacists have turned to a number of other tools to help patients access their prescriptions during the Covid-19 pandemic. The head of CVS Health’s specialty pharmacy strategy, Prem Shah, said he expects to see more patients continue receive healthcare at home after the pandemic ends. Though CVS Health had been building up its arsenal of digital tools before the Covid-19 pandemic, stay-at-home orders forced the pharmacy giant to lean mo...

Read More

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc | September 08, 2020

news image

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More

RESEARCH

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma | November 30, 2020

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More

PHARMACY MARKET

BOSTON SCIENTIFIC ANNOUNCES PARTNERSHIP DEFINITIVE AGREEMENT TO DIVEST BTG SPECIALTY PHARMACEUTICALS BUSINESS

Boston Scientific | December 02, 2020

news image

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "...

Read More
news image

CVS HEAD OF SPECIALTY PHARMACY SEES FUTURE OF HEALTHCARE AT HOME AFTER COVID-19

Medcity news | May 26, 2020

Mail-order prescriptions are nothing new, but pharmacists have turned to a number of other tools to help patients access their prescriptions during the Covid-19 pandemic. The head of CVS Health’s specialty pharmacy strategy, Prem Shah, said he expects to see more patients continue receive healthcare at home after the pandemic ends. Though CVS Health had been building up its arsenal of digital tools before the Covid-19 pandemic, stay-at-home orders forced the pharmacy giant to lean mo...

Read More
news image

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc | September 08, 2020

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More
news image

RESEARCH

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma | November 30, 2020

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More
news image

PHARMACY MARKET

BOSTON SCIENTIFIC ANNOUNCES PARTNERSHIP DEFINITIVE AGREEMENT TO DIVEST BTG SPECIALTY PHARMACEUTICALS BUSINESS

Boston Scientific | December 02, 2020

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "...

Read More